Market capitalization | $7.21m |
Enterprise Value | $7.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.42 |
P/S ratio (TTM) P/S ratio | 1.44 |
P/B ratio (TTM) P/B ratio | 3.34 |
Revenue growth (TTM) Revenue growth | -14.07% |
Revenue (TTM) Revenue | $5.02m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Genetic Technologies Limited Sponsored ADR:
1 Analyst has issued a forecast Genetic Technologies Limited Sponsored ADR:
Jun '24 |
+/-
%
|
||
Revenue | 5.02 5.02 |
14%
14%
|
|
Gross Profit | -2.91 -2.91 |
56%
56%
|
|
EBITDA | -7.66 -7.66 |
23%
23%
|
EBIT (Operating Income) EBIT | -8.01 -8.01 |
19%
19%
|
Net Profit | -7.87 -7.87 |
1%
1%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Head office | Australia |
CEO | Simon Morriss |
Employees | 60 |
Founded | 1987 |
Website | www.genetype.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.